Response to COVID-19 Vaccines Varies Widely in Blood Cancer Patients prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
Immunicum AB (publ) Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai
Immunicum AB (publ) Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai
Immunicum AB (publ; IMMU.ST) announced today the initiation of a research collaboration with the laboratory of Nina Bhardwaj, M.D., Ph.D., Director of Immunotherapy and the Medical Director of the Vaccine and Cell Therapy Core Facility, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York City.
Dr. Bhardwaj is a leading researcher who has made significant contributions to the field of human dendritic cells and specifically their mode of action. Her translational research has resulted in the development of receptor agonist- and dendritic cell-based vaccines for the treatment of both cancer and infectious diseases, and she has pioneered neoantigen vaccine studies at The Tisch Cancer Institute.
Related Company:
Vermont Business Magazine The Robert Larner, MD College of Medicine at The University of Vermont (UVM), in collaboration with the UVM Health Network (UVMHN) and the UVM Medical Center, has announced that Randall F Holcombe, MD, MBA, has been appointed director of the UVM Cancer Center (UVMCC) and chief of the Division of Hematology and Oncology in the Department of Medicine. Holcombe is expected to hold the newly established J Walter Juckett Chair in Cancer Research. He joins UVM and UVMHN from the National Cancer Institute (NCI)-designated University of Hawai i Cancer Center, where he has served as director since 2016.
Personalized Cancer Vaccine Guided by Mount Sinai Computations Is Safe, Shows Potential Benefit Against Multiple Tumor Types
Share Article
A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clinical trial presented during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, held April 10-15. NEW YORK (PRWEB) April 10, 2021 A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clin
Resistance to Immunotherapy in Patients with Urothelial Bladder Cancer Is Traced to Specific Sets of Immune Cells miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.